Spyre Therapeutics (SYRE) Stock Overview
A clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SYRE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Spyre Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$43.21 |
| 52 Week High | US$43.56 |
| 52 Week Low | US$10.91 |
| Beta | 3.16 |
| 1 Month Change | 34.88% |
| 3 Month Change | 60.22% |
| 1 Year Change | 102.96% |
| 3 Year Change | 341.14% |
| 5 Year Change | -76.80% |
| Change since IPO | -85.58% |
Recent News & Updates
Recent updates
Spyre Therapeutics: Validated Targets, Optimized Delivery
Jan 01Companies Like Spyre Therapeutics (NASDAQ:SYRE) Are In A Position To Invest In Growth
Jul 15
Spyre Therapeutics: Targeting The Future Of IBD Treatment
Mar 04Spyre Therapeutics: Different Name, Same Tune
Dec 12Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting
Oct 01Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely
Feb 24We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate
Oct 28Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase
Aug 18Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M
Aug 04Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?
Jun 09Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower
Dec 07Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts
Aug 10Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 08Shareholder Returns
| SYRE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.0% | 1.0% | 1.0% |
| 1Y | 103.0% | 26.2% | 14.6% |
Return vs Industry: SYRE exceeded the US Biotechs industry which returned 26.2% over the past year.
Return vs Market: SYRE exceeded the US Market which returned 14.6% over the past year.
Price Volatility
| SYRE volatility | |
|---|---|
| SYRE Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SYRE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SYRE's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 95 | Cameron Turtle | www.spyre.com |
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs.
Spyre Therapeutics, Inc. Fundamentals Summary
| SYRE fundamental statistics | |
|---|---|
| Market cap | US$3.39b |
| Earnings (TTM) | -US$126.54m |
| Revenue (TTM) | n/a |
Is SYRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYRE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$171.65m |
| Gross Profit | -US$171.65m |
| Other Expenses | -US$45.11m |
| Earnings | -US$126.54m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.61 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SYRE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/22 09:36 |
| End of Day Share Price | 2026/02/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Spyre Therapeutics, Inc. is covered by 23 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Mayur Somaiya | BMO Capital Markets Equity Research |
| Julian Harrison | BTIG |